Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Section: method Paragraph: Genotyping	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Our manuscript does not have cell experiments, so cell lines are not needed.	**n/a**
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	The blood samples of the laboratory patients in our manuscript do not need to be cultured.	**n/a**

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Our manuscript does not have animals experiments.	**n/a**
Animal observed in or captured from the field: Provide species, sex and age where possible	Our manuscript does not have animals experiments.	**n/a**
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	Our manuscript does not have animals experiments.	**n/a**

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Our manuscript does not have plants experiments.	**n/a**
Microbes: provide species and strain, unique accession number if available, and source	Our manuscript does not have microbes experiments.	**n/a**

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Clinical Trial and Biomedical Ethics Committee of West China Hospital of Sichuan University； No (198) trial 2014	
Provide statement confirming informed consent obtained from study participants.	Our manuscript does not require clinical trials, so provide statement is not required.	**n/a**
Report on age and sex for all study participants.	Figure 4A, B	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	Our manuscript does not require clinical trials.	**n/a**

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	Our manuscript does not need laboratory protocol.	**n/a**

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.	**Yes**	
Sample size determination	Section： results Paragraph: LncRNA AC007128.1 polymorphism associate with the susceptibility of PTB&EPTB	
Randomisation	Experimental design does not involve randomization.	**n/a**
Blinding	Experimental design does not involve blinding	**n/a**
Inclusion/exclusion criteria	Experimental design does not involve inclusion / exclusion criteria.	**n/a**

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Section: methods; Paragraph: genotyping 3SNPs (657 of PTB, 93 of EPTB, and 150 of PTB&EPTB)	
Define whether data describe technical or biological replicates	biological replicates	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Clinical Trial and Biomedical Ethics Committee of West China Hospital of Sichuan University； No (198) trial 2014	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Studies doesn't involve experimental animals	**n/a**
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Studies doesn't involve specimen and field samples	**n/a**

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	Study isn't subject to dual use research of concern.	**n/a**

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	**Section： Methods; Results** **Paragraph: GEO dataset reanalysis; AC007128.1 specifically expressed in TB patients** None of the samples or data points in the analysis were excluded.	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	**Section： Methods** **Paragraph: Statistical analysis** The Kruskal Wallis H test was used between groups, and the Wilcoxon Rank Sum test was used between two groups.	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Our manuscript does not have newly created datasets.	**n/a**
If data are publicly available, provide accession number in repository or DOI or URL.	Our manuscript does not publicly available data are reused.	**n/a**
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	**Section： results** **Paragraph:** **Differential expression of lncRNAs in TB & Biological function AC007128.1 in TB patients:** GSE98461. **AC007128.1 specifically expressed in TB patients:** GSE107231; GSE94519; GSE163980; GSE145227; GSE123932; GSE169256; GSE165934; GSE102541.	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	Our manuscript does not have code and software.	**n/a**
State whether the code or software is available.	Our manuscript does not have code and software.	**n/a**
If code is publicly available, provide accession number in repository, or DOI or URL.	Our manuscript does not have code and software.	**n/a**

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		**n/a**
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/atm-21-2724